2017
Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States
Mahal B, Chen Y, Muralidhar V, Mahal A, Choueiri T, Hoffman K, Hu J, Sweeney C, Yu J, Feng F, Kim S, Beard C, Martin N, Trinh Q, Nguyen P. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Annals Of Oncology 2017, 28: 1098-1104. PMID: 28453693, DOI: 10.1093/annonc/mdx041.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityProstate-specific antigenUnited States Preventive Services Task ForceRisk of prostate cancer-specific mortalityProstate cancer outcomesBlack raceMetastatic diseaseCancer outcomesProstate-specific antigen screeningRate of metastatic diseasePSA screening guidelinesCancer-specific mortalityRisk of poor outcomesStage of presentationPreventive Services Task ForceScreening-eligible ageMultivariate logistic regressionEligible populationNon-black menSEER databaseProstate cancerBlack menScreening guidelinesPoor outcomeRisk regressionRacial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.
Mahal B, Chen Y, Muralidhar V, Mahal A, Choueiri T, Hoffman K, Hu J, Sweeney C, Beard C, Martin N, Feng F, Kim S, Yu J, Trinh Q, Nguyen P. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Journal Of Clinical Oncology 2017, 35: 18-18. DOI: 10.1200/jco.2017.35.6_suppl.18.Peer-Reviewed Original ResearchProstate cancer-specific mortalityProstate-specific antigenRisk of prostate cancer-specific mortalityProstate-specific antigen screeningProstate cancer outcomesUnited States Preventive Services Task ForceBlack raceMetastatic diseaseCancer outcomesRate of metastatic diseaseCancer-specific mortalityStage of presentationRisk of poor outcomesPreventive Services Task ForceScreening-eligible ageMultivariate logistic regressionEligible populationNon-black menProstate-specificSEER databaseProstate cancerBlack menPoor outcomeRisk regressionBlack patients
2015
Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?
Mahal B, Muralidhar V, Chen Y, Choueiri T, Hoffman K, Hu J, Sweeney C, Yu J, Feng F, Trinh Q, Nguyen P. Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9? BJU International 2015, 118: 95-101. PMID: 26207642, DOI: 10.1111/bju.13239.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityGleason score 5Risk of prostate cancer-specific mortalityGleason score 4Prostate cancerScore 5Increased risk of PCSMGray competing risk regression analysisProstate cancer-specific mortality outcomesProstate cancer-specific mortality ratesScore 4Competing risk regression analysisGleason score 3Gleason score 8Gleason score 9Primary Gleason patternReference group of patientsCancer-specific mortalityAggressive treatment strategiesGroup of patientsRisk regression analysisHighest-risk patientsGleason 4Gleason scoreGleason pattern